{
    "id": 29330,
    "fullName": "SMO D473Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SMO D473Y lies within the ligand-binding pocket of the Smo protein (PMID: 25759020). D473Y is predicted to confer resistance to Hedgehog pathway inhibitors based on structural modeling (PMID: 2506392), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Apr 2020).",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                },
                {
                    "id": 14065,
                    "pubMedId": 2506392,
                    "title": "A successful delivery of an extremely immature infant in Rh incompatibility after plasma exchange.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/2506392"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "D473Y",
    "createDate": "02/12/2019",
    "updateDate": "04/02/2020",
    "referenceTranscriptCoordinates": {
        "id": 178553,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129209348G>T",
        "cDna": "c.1417G>T",
        "protein": "p.D473Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15948,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a de novo SMO D473Y mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial 11-month complete clinical response to Erivedge (vismodegib) during a Phase II trial (PMID: 25306392; NCT01367665).",
            "molecularProfile": {
                "id": 31332,
                "profileName": "SMO D473Y"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 2513,
                "name": "basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12487,
                    "pubMedId": 25306392,
                    "title": "Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25306392"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31332,
            "profileName": "SMO D473Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 178553,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129209348G>T",
            "cDna": "c.1417G>T",
            "protein": "p.D473Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}